|
1
|
Meacham CE and Morrison SJ: Tumour
heterogeneity and cancer cell plasticity. Nature. 501:328–337.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bodzin AS and Busuttil RW: Hepatocellular
carcinoma: Advances in diagnosis, management, and long term
outcome. World J Hepatol. 7:1157–1167. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Slotta JE, Kollmar O, Ellenrieder V,
Ghadimi BM and Homayounfar K: Hepatocellular carcinoma: Surgeon's
view on latest findings and future perspectives. World J Hepatol.
7:1168–1183. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oda K, Uto H, Mawatari S and Ido A:
Clinical features of hepatocellular carcinoma associated with
nonalcoholic fatty liver disease: A review of human studies. Clin J
Gastroenterol. 8:1–9. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Choi KJ, Baik IH, Ye SK and Lee YH:
Molecular targeted therapy for hepatocellular carcinoma: Present
status and future directions. Biol Pharm Bull. 38:986–991. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang Y: Identification of differentially
expressed genes in hepatocellular carcinoma by laser capture
microdissection and microarrayGuangzhou Medical University;
2009
|
|
9
|
Fry AM: The Nek2 protein kinase: A novel
regulator of centrosome structure. Oncogene. 21:6184–6194. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schultz SJ, Fry AM, Sütterlin C, Ried T
and Nigg EA: Cell cycle-dependent expression of Nek2, a novel human
protein kinase related to the NIMA mitotic regulator of Aspergillus
nidulans. Cell Growth Differ. 5:625–635. 1994.PubMed/NCBI
|
|
11
|
Uto K and Sagata N: Nek2B, a novel
maternal form of Nek2 kinase, is essential for the assembly or
maintenance of centrosomes in early Xenopus embryos. Embo J.
19:1816–1826. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fry AM, Schultz SJ, Bartek J and Nigg EA:
Substrate specificity and cell cycle regulation of the Nek2 protein
kinase, a potential human homolog of the mitotic regulator NIMA of
Aspergillus nidulans. J Biol Chem. 270:12899–12905. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fletcher L, Cerniglia GJ, Nigg EA, Yend TJ
and Muschel RJ: Inhibition of centrosome separation after DNA
damage: A role for Nek2. Radiat Res. 162:128–135. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bowers AJ and Boylan JF: Nek8, a NIMA
family kinase member, is overexpressed in primary human breast
tumors. Gene. 328:135–142. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kokuryo T, Senga T, Yokoyama Y, Nagino M,
Nimura Y and Hamaguchi M: Nek2 as an effective target for
inhibition of tumorigenic growth and peritoneal dissemination of
cholangiocarcinoma. Cancer Res. 67:9637–9642. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Suzuki K, Kokuryo T, Senga T, Yokoyama Y,
Nagino M and Hamaguchi M: Novel combination treatment for
colorectal cancer using Nek2 siRNA and cisplatin. Cancer Sci.
101:1163–1169. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tsunoda N, Kokuryo T, Oda K, Senga T,
Yokoyama Y, Nagino M, Nimura Y and Hamaguchi M: Nek2 as a novel
molecular target for the treatment of breast carcinoma. Cancer Sci.
100:111–116. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Drozdov I, Bornschein J, Wex T, Valeyev
NV, Tsoka S and Malfertheiner P: Functional and topological
properties in hepatocellular carcinoma transcriptome. Plos One.
7:e355102012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gu Z, Zhou W, Huang J, Yang Y, Wendlandt
E, Xu H, He X, Tricot G and Zhan F: Nek2 is a novel regulator of B
cell development and immunological response. Biomed Res Int.
2014:6210822014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wai DH, Schaefer KL, Schramm A, Korsching
E, Van Valen F, Ozaki T, Boecker W, Schweigerer L,
Dockhorn-Dworniczak B and Poremba C: Expression analysis of
pediatric solid tumor cell lines using oligonucleotide microarrays.
Int J Oncol. 20:441–451. 2002.PubMed/NCBI
|
|
21
|
Andreasson U, Dictor M, Jerkeman M,
Berglund M, Sundström C, Linderoth J, Rosenquist R, Borrebaeck CA
and Ek S: Identification of molecular targets associated with
transformed diffuse large B cell lymphoma using highly purified
tumor cells. Am J Hematol. 84:803–888. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Marina M and Saavedra HI: Nek2 and Plk4:
Prognostic markers, drivers of breast tumorigenesis and drug
resistance. Front Biosci (Landmark Ed). 19:352–365. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu W, Baxter JE, Wattam SL, Hayward DG,
Fardilha M, Knebel A, Ford EM, da Cruz e Silva EF and Fry AM:
Alternative splicing controls nuclear translocation of the cell
cycle-regulated Nek2 kinase. J Biol Chem. 282:26431–26440. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Das TK, Dana D, Paroly SS, Perumal SK,
Singh S, Jhun H, Pendse J, Cagan RL, Talele TT and Kumar S:
Centrosomal kinase Nek2 cooperates with oncogenic pathways to
promote metastasis. Oncogenesis. 2:e692013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mbom BC, Nelson WJ and Barth A: β-catenin
at the centrosome: Discrete pools of β-catenin communicate during
mitosis and may co-ordinate centrosome functions and cell cycle
progression. Bioessays. 35:804–969. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rapley J, Baxter JE, Blot J, Wattam SL,
Casenghi M, Meraldi P, Nigg EA and Fry AM: Coordinate regulation of
the mother centriole component nlp by nek2 and plk1 protein
kinases. Mol Cell Biol. 25:1309–1324. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hayward DG and Fry AM: Nek2 kinase in
chromosome instability and cancer. Cancer Lett. 237:155–166. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mbom BC, Siemers KA, Ostrowski MA, Nelson
WJ and Barth AI: Nek2 phosphorylates and stabilizes β-catenin at
mitotic centrosomes downstream of Plk1. Mol Biol Cell. 25:977–991.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Olmeda D, Castel S, Vilaro S and Cano A:
β-catenin regulation during the cell cycle: Implications in G2/M
and apoptosis. Mol Biol Cell. 14:2844–2860. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gehrke I, Gandhirajan RK and Kreuzer KA:
Targeting the WNT/β-catenin/TCF/LEF1 axis in solid and
haematological cancers: Multiplicity of therapeutic options. Eur J
Cancer. 45:2759–2767. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sekiya T, Nakamura T, Kazuki Y, Oshimura
M, Kohu K, Tago K, Ohwada S and Akiyama T: Overexpression of Icat
induces G(2) arrest and cell death in tumor cell mutants for
adenomatous polyposis coli, β-catenin, or Axin. Cancer Res.
62:3322–3326. 2002.PubMed/NCBI
|
|
32
|
Chou J, Lin YC, Kim J, You L, Xu Z, He B
and Jablons DM: Nasopharyngeal carcinoma-review of the molecular
mechanisms of tumorigenesis. Head Neck. 30:946–963. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Salomon A, Keramidas M, Maisin C and
Thomas M: Loss of β-catenin in adrenocortical cancer cells causes
growth inhibition and reversal of epithelial-to-mesenchymal
transition. Oncotarget. 6:11421–11433. 2015. View Article : Google Scholar : PubMed/NCBI
|
